BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28867179)

  • 21. KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis.
    Yuan P; He XH; Rong YF; Cao J; Li Y; Hu YP; Liu Y; Li D; Lou W; Liu MF
    Cancer Res; 2017 Jan; 77(1):100-111. PubMed ID: 27793842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis.
    Rajurkar M; Dang K; Fernandez-Barrena MG; Liu X; Fernandez-Zapico ME; Lewis BC; Mao J
    Cancer Res; 2017 Jan; 77(2):320-329. PubMed ID: 28069799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RAGE Up-Regulation Differently Affects Cell Proliferation and Migration in Pancreatic Cancer Cells.
    Swami P; Thiyagarajan S; Vidger A; Indurthi VSK; Vetter SW; Leclerc E
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33086527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deregulation of the MiR-193b-KRAS Axis Contributes to Impaired Cell Growth in Pancreatic Cancer.
    Jin X; Sun Y; Yang H; Li J; Yu S; Chang X; Lu Z; Chen J
    PLoS One; 2015; 10(4):e0125515. PubMed ID: 25905463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice.
    Martinelli P; Madriles F; Cañamero M; Pau EC; Pozo ND; Guerra C; Real FX
    Gut; 2016 Mar; 65(3):476-86. PubMed ID: 25596178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma.
    Liang C; Qin Y; Zhang B; Ji S; Shi S; Xu W; Liu J; Xiang J; Liang D; Hu Q; Ni Q; Xu J; Yu X
    Mol Cancer Res; 2017 Feb; 15(2):201-212. PubMed ID: 28108627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network.
    Ying H; Elpek KG; Vinjamoori A; Zimmerman SM; Chu GC; Yan H; Fletcher-Sananikone E; Zhang H; Liu Y; Wang W; Ren X; Zheng H; Kimmelman AC; Paik JH; Lim C; Perry SR; Jiang S; Malinn B; Protopopov A; Colla S; Xiao Y; Hezel AF; Bardeesy N; Turley SJ; Wang YA; Chin L; Thayer SP; DePinho RA
    Cancer Discov; 2011 Jul; 1(2):158-69. PubMed ID: 21984975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased SPRY1 expression activates NF-κB signaling and promotes pancreatic cancer progression by recruiting neutrophils and macrophages through CXCL12-CXCR4 axis.
    Shi T; Li X; Zheng J; Duan Z; Ooi YY; Gao Y; Wang Q; Yang J; Wang L; Yao L
    Cell Oncol (Dordr); 2023 Aug; 46(4):969-985. PubMed ID: 37014552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncogenic KRas-induced Increase in Fluid-phase Endocytosis is Dependent on N-WASP and is Required for the Formation of Pancreatic Preneoplastic Lesions.
    Lubeseder-Martellato C; Alexandrow K; Hidalgo-Sastre A; Heid I; Boos SL; Briel T; Schmid RM; Siveke JT
    EBioMedicine; 2017 Feb; 15():90-99. PubMed ID: 28057438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis.
    Santana-Codina N; Roeth AA; Zhang Y; Yang A; Mashadova O; Asara JM; Wang X; Bronson RT; Lyssiotis CA; Ying H; Kimmelman AC
    Nat Commun; 2018 Nov; 9(1):4945. PubMed ID: 30470748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer.
    Kapoor A; Yao W; Ying H; Hua S; Liewen A; Wang Q; Zhong Y; Wu CJ; Sadanandam A; Hu B; Chang Q; Chu GC; Al-Khalil R; Jiang S; Xia H; Fletcher-Sananikone E; Lim C; Horwitz GI; Viale A; Pettazzoni P; Sanchez N; Wang H; Protopopov A; Zhang J; Heffernan T; Johnson RL; Chin L; Wang YA; Draetta G; DePinho RA
    Cell; 2014 Jul; 158(1):185-197. PubMed ID: 24954535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.
    Viale A; Pettazzoni P; Lyssiotis CA; Ying H; Sánchez N; Marchesini M; Carugo A; Green T; Seth S; Giuliani V; Kost-Alimova M; Muller F; Colla S; Nezi L; Genovese G; Deem AK; Kapoor A; Yao W; Brunetto E; Kang Y; Yuan M; Asara JM; Wang YA; Heffernan TP; Kimmelman AC; Wang H; Fleming JB; Cantley LC; DePinho RA; Draetta GF
    Nature; 2014 Oct; 514(7524):628-32. PubMed ID: 25119024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
    Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
    J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Designing and developing S100P inhibitor 5-methyl cromolyn for pancreatic cancer therapy.
    Arumugam T; Ramachandran V; Sun D; Peng Z; Pal A; Maxwell DS; Bornmann WG; Logsdon CD
    Mol Cancer Ther; 2013 May; 12(5):654-62. PubMed ID: 23303403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells.
    Xu D; Allsop SA; Witherspoon SM; Snider JL; Yeh JJ; Fiordalisi JJ; White CD; Williams D; Cox AD; Baines AT
    Carcinogenesis; 2011 Apr; 32(4):488-95. PubMed ID: 21262926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops.
    Eibl G; Rozengurt E
    Semin Cancer Biol; 2019 Feb; 54():50-62. PubMed ID: 29079305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.
    Tanaka M; Suzuki HI; Shibahara J; Kunita A; Isagawa T; Yoshimi A; Kurokawa M; Miyazono K; Aburatani H; Ishikawa S; Fukayama M
    Oncogene; 2014 May; 33(19):2454-63. PubMed ID: 23752186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice.
    Grippo PJ; Fitchev PS; Bentrem DJ; Melstrom LG; Dangi-Garimella S; Krantz SB; Heiferman MJ; Chung C; Adrian K; Cornwell ML; Flesche JB; Rao SM; Talamonti MS; Munshi HG; Crawford SE
    Gut; 2012 Oct; 61(10):1454-64. PubMed ID: 22234980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KRAS-regulated glutamine metabolism requires UCP2-mediated aspartate transport to support pancreatic cancer growth.
    Raho S; Capobianco L; Malivindi R; Vozza A; Piazzolla C; De Leonardis F; Gorgoglione R; Scarcia P; Pezzuto F; Agrimi G; Barile SN; Pisano I; Reshkin SJ; Greco MR; Cardone RA; Rago V; Li Y; Marobbio CMT; Sommergruber W; Riley CL; Lasorsa FM; Mills E; Vegliante MC; De Benedetto GE; Fratantonio D; Palmieri L; Dolce V; Fiermonte G
    Nat Metab; 2020 Dec; 2(12):1373-1381. PubMed ID: 33230296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RAGE-specific single chain Fv for PET imaging of pancreatic cancer.
    Kim HY; Wang X; Kang R; Tang D; Boone BA; Zeh HJ; Lotze MT; Edwards WB
    PLoS One; 2018; 13(3):e0192821. PubMed ID: 29529089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.